martin
martin
PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases
New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions
PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease
Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease
PharmaKure and Universiti Teknologi MARA (UiTM) Announce a Research Partnership To Advance Research in Alzheimer’s Disease Diagnosis
The partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease.
Speaker Announcement: Dr Farid Khan, Chief Executive of PharmaKure at Biotech Outsourcing Strategies Manchester 2023
Talk to focus on the spinout journey from drug repurposing to clinical trials for diagnosing and treating Alzheimer’s Disease